Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Cash & Equivalents (2019 - 2025)

Historic Cash & Equivalents for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to $37.8 million.

  • Allogene Therapeutics' Cash & Equivalents fell 2619.88% to $37.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.8 million, marking a year-over-year decrease of 2619.88%. This contributed to the annual value of $75.2 million for FY2024, which is 954.48% down from last year.
  • According to the latest figures from Q3 2025, Allogene Therapeutics' Cash & Equivalents is $37.8 million, which was down 2619.88% from $52.3 million recorded in Q2 2025.
  • In the past 5 years, Allogene Therapeutics' Cash & Equivalents registered a high of $236.9 million during Q1 2021, and its lowest value of $37.8 million during Q3 2025.
  • For the 5-year period, Allogene Therapeutics' Cash & Equivalents averaged around $107.3 million, with its median value being $83.2 million (2023).
  • Per our database at Business Quant, Allogene Therapeutics' Cash & Equivalents surged by 7429.74% in 2021 and then tumbled by 6933.68% in 2025.
  • Quarter analysis of 5 years shows Allogene Therapeutics' Cash & Equivalents stood at $173.3 million in 2021, then crashed by 64.28% to $61.9 million in 2022, then skyrocketed by 34.33% to $83.2 million in 2023, then decreased by 9.54% to $75.2 million in 2024, then tumbled by 49.73% to $37.8 million in 2025.
  • Its Cash & Equivalents stands at $37.8 million for Q3 2025, versus $52.3 million for Q2 2025 and $42.5 million for Q1 2025.